Piruntha Thiyagarajah

Also affiliated with Immunocore (United Kingdom)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer”.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01308

N/A

7.3DataRank · unranked

1324 citations

Corinne Faivre‐Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz‐Ares +20 more

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015

N/A

6.9DataRank · unranked

471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.02.009

N/A

0.710DataRank · unranked

113 citations

Scott Antonia, Yi-Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann +3 more